{"entity":{"id":"nct02637687","kind":"trial","name":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","aka":["SCOUT"],"tldr":"A phase 1/2 trial of Larotrectinib in advanced solid tumours, run by Bayer, active and no longer recruiting.","summary":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children is a phase 1/2 interventional study registered as NCT02637687 by Bayer, with 154 participants enrolled, started 2015-12-16 and due to reach its primary completion in 2024-07-20. Interventions recorded: Larotrectinib (Vitrakvi, BAY2757556).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02637687","url":"https://clinicaltrials.gov/study/NCT02637687"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["cgp","kinase-inhibitors"],"targets":[],"drugs":["larotrectinib"],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02637687","phase":"1/2","setting":"A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors","sponsor":"Bayer","participation":[{"nct":"NCT02637687","source":"https://clinicaltrials.gov/study/NCT02637687","fetchedAt":"2026-10-07T16:52:49.296Z","studySha256":"755fd34e8c1cde418c0e5728902ae1a50bd2be523d33b2b1383ec99f5eb845a7","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-06-22","leadSponsor":"Bayer","collaboratorCount":0,"maximumAge":"21 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":154,"enrolmentType":"ACTUAL","siteCount":45,"recruitingSiteCount":0,"countries":["Australia","Canada","China","Czechia","Denmark","France","Germany","Ireland","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","Ukraine","United Kingdom","United States"]}],"started":"2015-12-16","startedType":"actual","enrolled":154,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02637687/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"}]}}